Class Action Lawsuit Filed Against ADMA Biologics Amid Allegations of Securities Fraud

A class action lawsuit has been filed against ADMA Biologics (NASDAQ: ADMA) over alleged securities fraud and misleading business practices. The firm Pomerantz LLP is representing investors who suffered losses during the specified Class Period, with a deadline for lead plaintiff applications on August 10, 2026.

By Pomerantz LLP · PR Newswire · July 23, 2026, 14:00 UTC

Tickers: $ADMA

Topics: class action securities fraud stock price decline

Read the full article at PR Newswire

More Politics news

Pomerantz Law Firm Investigates HCA Healthcare Following Reduced Profit Guidance PR Newswire · November 12, 2026, 16:25 UTC
Pomerantz Law Firm Investigates Greenland Energy (GLND) Following Short Seller Report PR Newswire · November 12, 2026, 16:15 UTC
Pomerantz Law Firm Investigates Potential Securities Fraud at Foghorn Therapeutics (FHTX) PR Newswire · November 12, 2026, 16:00 UTC
Pomerantz Law Firm Investigates VinFast Auto Ltd. Following Significant Operating Losses PR Newswire · November 12, 2026, 15:55 UTC
Class Action Lawsuit Filed Against Skechers U.S.A., Inc. Regarding Take-Private Acquisition PR Newswire · November 12, 2026, 15:00 UTC
Class Action Lawsuit Filed Against Compass, Inc. Regarding Merger Disclosures PR Newswire · November 12, 2026, 15:00 UTC
Scott Colom Defeats Incumbent Cindy Hyde-Smith in Mississippi Senate Election CNBC · November 11, 2026, 23:03 UTC
Advocacy Groups Prepare to Pressure Politicians Over Data Center Restrictions Following Midterm Elections The Verge · November 11, 2026, 21:56 UTC
Alleged Security Concerns Involving Nvidia CEO Jensen Huang Prompt US-Taiwan Official Concern The Verge · November 11, 2026, 19:22 UTC
Scott Colom Maintains Narrow Lead Over Cindy Hyde-Smith in Mississippi Senate Race CNBC · November 10, 2026, 21:55 UTC